High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients

Condition:   Hypercholesterolemia
Intervention:   Drug: DW-3102
Sponsor:   Daewon Pharmaceutical Co., Ltd.
Not yet recruiting - verified February 2015

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Condition:   Hypercholesterolemia
Interventions:   Drug: CAT-2054;   Drug: Placebo
Sponsor:   Catabasis Pharmaceuticals
Recruiting - verified February 2015

Study of Normal Hip and Lumbar Bone Marrow With Dynamic Contrast Enhancement Magnetic Resonance Imaging

Condition:   Bone Marrow
Intervention:   Other: MRI sequence
Sponsor:   University Hospital, Lille
Completed - verified February 2015

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Conditions:   Vascular Diseases;   Hypercholesterolemia;   Diabetes Mellitus
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Placebo product
Sponsors:   Unilever R&D;   CSIRO
Recruiting - verified September 2014

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Condition:   Hyperlipidemia
Interventions:   Drug: Evacetrapib;   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2015

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)

Condition:   Dyslipidaemia
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Hypertriglyceridaemia - Cause and Effects

Condition:   Hypertriglyceridaemia
Intervention:  
Sponsor:   Central Manchester University Hospitals NHS Foundation Trust
Recruiting - verified February 2015

Carnitine for the Treatment of Atherosclerosis.

Condition:   Metabolic Syndrome
Interventions:   Dietary Supplement: L-carnitine capsules;   Dietary Supplement: Lactose capsules
Sponsors:   Queen's University;   Heart and Stroke Foundation of Canada
Recruiting - verified March 2015

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2015

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2015

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified February 2015

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Condition:   Severe Familial Hypercholesterolemia
Interventions:   Biological: Evolocumab (AMG145);   Biological: Evolocumab (AMG145)
Sponsor:   Amgen
Recruiting - verified February 2015

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Anesthesia;   Pain;   Reflux;   Nausea;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma
Intervention:   Drug: Ampicillin
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation
Recruiting - verified February 2015

A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions:   Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
Sponsors:   Merck Sharp & Dohme Corp.;   Bayer
Completed - verified February 2015

A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions:   Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
Sponsors:   Merck Sharp & Dohme Corp.;   Bayer
Completed - verified February 2015

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Conditions:   Hypercholesterolemia;   Hyperlipidemia
Intervention:   Drug: MK0859
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2015

MK0859 Dose-Ranging Study (0859-003)

Conditions:   Hypercholesterolemia;   Mixed Hyperlipemia
Intervention:   Drug: MK0859
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2015

Get CardioSmart

You're Invited